Repligen Co. (NASDAQ:RGEN) Position Boosted by Blue Trust Inc.

Blue Trust Inc. lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 113.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 239 shares of the biotechnology company’s stock after purchasing an additional 127 shares during the period. Blue Trust Inc.’s holdings in Repligen were worth $36,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of RGEN. Norden Group LLC lifted its position in shares of Repligen by 38.7% during the first quarter. Norden Group LLC now owns 2,972 shares of the biotechnology company’s stock worth $547,000 after purchasing an additional 830 shares during the last quarter. Diversify Advisory Services LLC bought a new position in Repligen in the first quarter worth about $323,000. BNP Paribas Financial Markets lifted its holdings in Repligen by 494.0% in the first quarter. BNP Paribas Financial Markets now owns 80,399 shares of the biotechnology company’s stock worth $14,787,000 after acquiring an additional 66,864 shares during the last quarter. Connecticut Wealth Management LLC bought a new position in Repligen in the first quarter worth about $201,000. Finally, Fidelis Capital Partners LLC bought a new position in Repligen in the first quarter worth about $115,000. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $138.61 on Friday. The stock has a market cap of $7.76 billion, a price-to-earnings ratio of -3,355.91, a PEG ratio of 3.92 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The stock’s 50 day moving average price is $142.20 and its 200 day moving average price is $146.15.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same quarter in the prior year, the firm posted $0.53 earnings per share. The company’s revenue was down 3.2% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company began coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. UBS Group cut their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.